Novozymes Future Growth

Future criteria checks 3/6

Novozymes is forecast to grow earnings and revenue by 17.7% and 12.9% per annum respectively. EPS is expected to grow by 7% per annum. Return on equity is forecast to be 8.3% in 3 years.

Key information

17.7%

Earnings growth rate

7.0%

EPS growth rate

Chemicals earnings growth	21.6%
Revenue growth rate	12.9%
Future return on equity	8.3%
Analyst coverage	Good
Last updated	03 May 2024

Recent future growth updates

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29

Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Apr 12

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 01

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

Feb 14

Is Novozymes A/S (CPH:NZYM B) Worth kr.537 Based On Its Intrinsic Value?

Jan 01

We Think Novozymes (CPH:NZYM B) Can Stay On Top Of Its Debt

Nov 28

Many Would Be Envious Of Novozymes' (CPH:NZYM B) Excellent Returns On Capital

Nov 11

Earnings and Revenue Growth Forecasts

CPSE:NSIS B - Analysts future estimates and past financials data (DKK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	33,368	6,082	6,485	9,641	6
12/31/2025	29,948	4,987	5,355	8,512	8
12/31/2024	27,207	3,840	4,233	6,811	9
12/31/2023	17,899	3,024	2,097	4,152	N/A
9/30/2023	17,825	3,209	1,263	3,614	N/A
6/30/2023	17,736	3,425	616	3,248	N/A
3/31/2023	17,805	3,628	618	3,545	N/A
12/31/2022	17,553	3,676	1,116	4,006	N/A
9/30/2022	16,858	3,418	1,528	4,117	N/A
6/30/2022	16,252	3,108	1,946	4,007	N/A
3/31/2022	15,546	3,093	2,504	3,939	N/A
12/31/2021	14,951	3,146	2,822	4,062	N/A
9/30/2021	14,563	3,175	3,428	4,413	N/A
6/30/2021	14,233	3,044	3,209	4,197	N/A
3/31/2021	14,002	2,895	3,293	4,290	N/A
12/31/2020	14,012	2,825	3,415	4,355	N/A
9/30/2020	14,297	3,093	3,294	3,881	N/A
6/30/2020	14,570	3,020	3,463	3,997	N/A
3/31/2020	14,679	3,273	3,035	3,596	N/A
12/31/2019	14,374	3,154	2,629	3,196	N/A
9/30/2019	14,357	3,069	2,358	3,436	N/A
6/30/2019	14,311	3,238	2,616	3,768	N/A
3/31/2019	14,351	3,116	2,305	3,558	N/A
12/31/2018	14,390	3,226	2,287	3,679	N/A
9/30/2018	14,349	3,183	2,258	3,839	N/A
6/30/2018	14,271	3,194	1,954	3,649	N/A
3/31/2018	14,311	3,154	2,048	3,738	N/A
12/31/2017	14,531	3,119	2,371	4,063	N/A
9/30/2017	14,572	3,131	N/A	3,963	N/A
6/30/2017	14,382	3,063	N/A	3,883	N/A
3/31/2017	14,273	3,077	N/A	4,073	N/A
12/31/2016	14,142	3,050	N/A	3,840	N/A
9/30/2016	13,880	2,936	N/A	3,632	N/A
6/30/2016	14,012	2,929	N/A	3,248	N/A
3/31/2016	14,032	2,861	N/A	3,353	N/A
12/31/2015	14,002	2,823	N/A	3,339	N/A
9/30/2015	13,731	2,734	N/A	2,945	N/A
6/30/2015	13,393	2,630	N/A	3,308	N/A
3/31/2015	13,005	2,539	N/A	3,391	N/A
12/31/2014	12,459	2,526	N/A	4,525	N/A
9/30/2014	12,218	2,484	N/A	5,061	N/A
6/30/2014	11,970	2,413	N/A	4,791	N/A
3/31/2014	11,934	2,379	N/A	4,235	N/A
12/31/2013	11,746	2,200	N/A	2,599	N/A
9/30/2013	11,617	2,132	N/A	2,547	N/A
6/30/2013	11,519	2,085	N/A	2,531	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NSIS B's forecast earnings growth (17.7% per year) is above the savings rate (0.9%).

Earnings vs Market: NSIS B's earnings (17.7% per year) are forecast to grow faster than the Danish market (14.4% per year).

High Growth Earnings: NSIS B's earnings are forecast to grow, but not significantly.

Revenue vs Market: NSIS B's revenue (12.9% per year) is forecast to grow faster than the Danish market (11.2% per year).

High Growth Revenue: NSIS B's revenue (12.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NSIS B's Return on Equity is forecast to be low in 3 years time (8.3%).

Novozymes Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novonesis Provides Earnings Guidance for the Year 2024

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Recent updates

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Consensus EPS estimates increase by 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent